- Home
- NRO vs CRVO Comparison
NRO vs CRVO Comparison
Compare NRO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CRVO
- Stock Information
- Founded
- NRO 2003
- CRVO 2001
- Country
- NRO United States
- CRVO United States
- Employees
- NRO N/A
- CRVO N/A
- Industry
- NRO Finance/Investors Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- CRVO Health Care
- Exchange
- NRO Nasdaq
- CRVO Nasdaq
- Market Cap
- NRO 187.8M
- CRVO 98.3M
- IPO Year
- NRO N/A
- CRVO N/A
- Fundamental
- Price
- NRO $3.50
- CRVO $2.13
- Analyst Decision
- NRO
- CRVO Buy
- Analyst Count
- NRO 0
- CRVO 8
- Target Price
- NRO N/A
- CRVO $38.75
- AVG Volume (30 Days)
- NRO 239.4K
- CRVO 476.7K
- Earning Date
- NRO 01-01-0001
- CRVO 11-12-2024
- Dividend Yield
- NRO 11.41%
- CRVO N/A
- EPS Growth
- NRO N/A
- CRVO N/A
- EPS
- NRO N/A
- CRVO N/A
- Revenue
- NRO N/A
- CRVO $10,066,550.00
- Revenue This Year
- NRO N/A
- CRVO $34.17
- Revenue Next Year
- NRO N/A
- CRVO N/A
- P/E Ratio
- NRO N/A
- CRVO N/A
- Revenue Growth
- NRO N/A
- CRVO 116.29
- 52 Week Low
- NRO $2.51
- CRVO $1.80
- 52 Week High
- NRO $3.45
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- NRO 42.49
- CRVO 28.45
- Support Level
- NRO $3.52
- CRVO $1.99
- Resistance Level
- NRO $3.62
- CRVO $2.43
- Average True Range (ATR)
- NRO 0.08
- CRVO 0.17
- MACD
- NRO 0.01
- CRVO 0.31
- Stochastic Oscillator
- NRO 40.00
- CRVO 26.92
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.